gastroenteropancreatic neuroendocrine tumors

Radioactive drug for digestive cancer snags FDA approvalFDA approved a new drug to treat a type of cancer that affects the pancreas or gastrointestinal tract.
FDA approves first therapy for treating patients with GEP-NETsFDA has approved lanreotide (Somatuline Depot, Ipsen) Injection, 120 mg (referred to as Somatuline) for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
FDA drug approvals December 2014